RESUMEN
Background: Obesity is prevalent among patients with hypertrophic cardiomyopathy (HCM). Obese HCM patients have greater wall thickness, LV mass, worse hemodynamic function and NYHA class. Weight loss may favorably influence the HCM phenotype. Case summary: We describe six patients with hypertrophic cardiomyopathy who lost weight through diet and lifestyle changes (n = 4) or bariatric surgery (n = 2). Radiographic imaging, with cardiac MRI or CT scan, was performed before and after their weight loss. There was a mean decrease in LV mass and indexed LV mass, and a mean numerical decrease in mean wall thickness in up to 14 out of 18 LV segments. There was also NYHA class reduction in symptoms. Discussion: In this case series, we have shown that substantial weight loss in HCM patients can be associated with a decrease in LV mass, wall thickness and improvement in symptoms. These observations indicate the potential for positive remodeling of the heart by weight loss. Prospective studies of the benefits of weight loss in HCM are needed.
RESUMEN
CASE PRESENTATION: A 52-year-old man came to the cardiac surgery clinic for pulmonary thromboendarterectomy (PTE) evaluation. He had initially appeared at an outside hospital 1 year earlier, with chest pain and shortness of breath. He had no known chronic conditions. A CT pulmonary angiogram (CTPA) at that time showed a filling defect at the bifurcation of the main pulmonary artery. A transthoracic echocardiogram revealed mild mitral valve regurgitation, but otherwise the results were normal. As he was hemodynamically stable and not hypoxemic, he was treated solely by anticoagulation. Despite adhering to prescribed apixaban, he developed progressive dyspnea and reduced exercise tolerance over the subsequent year. A repeat CTPA performed 12 months after the initial presentation showed a persistent filling defect at the level of the pulmonary artery bifurcation, with a new extension now completely occluding the right main pulmonary artery. A pulmonary angiogram confirmed this complete occlusion, and right heart catheterization revealed precapillary pulmonary hypertension, with a mean pulmonary artery pressure of 50 mm Hg. His anticoagulation was transitioned to enoxaparin for presumed apixaban treatment failure, and an investigation for hypercoagulable conditions was initiated. His lupus anticoagulant test result was positive, but he did not meet the criteria for antiphospholipid syndrome because he was negative for anticardiolipin and ß2-glycoprotein antibodies. Assays for antithrombin III, protein C, prothrombin gene, and factor V Leiden mutations produced normal results.
Asunto(s)
Disnea , Endarterectomía , Humanos , Masculino , Persona de Mediana Edad , Anticoagulantes/uso terapéutico , Dolor en el Pecho/diagnóstico , Dolor en el Pecho/etiología , Disnea/diagnóstico , Disnea/etiologíaRESUMEN
BACKGROUND AND OBJECTIVES: Infections play a key role in the development of Guillain-Barré syndrome (GBS) and have been associated with specific clinical features and disease severity. The clinical variation of GBS across geographical regions has been suggested to be related to differences in the distribution of preceding infections, but this has not been studied on a large scale. METHODS: We analyzed the first 1,000 patients included in the International GBS Outcome Study with available biosamples (n = 768) for the presence of a recent infection with Campylobacter jejuni, hepatitis E virus, Mycoplasma pneumoniae, cytomegalovirus, and Epstein-Barr virus. RESULTS: Serologic evidence of a recent infection with C. jejuni was found in 228 (30%), M. pneumoniae in 77 (10%), hepatitis E virus in 23 (3%), cytomegalovirus in 30 (4%), and Epstein-Barr virus in 7 (1%) patients. Evidence of more than 1 recent infection was found in 49 (6%) of these patients. Symptoms of antecedent infections were reported in 556 patients (72%), and this proportion did not significantly differ between those testing positive or negative for a recent infection. The proportions of infections were similar across continents. The sensorimotor variant and the demyelinating electrophysiologic subtype were most frequent across all infection groups, although proportions were significantly higher in patients with a cytomegalovirus and significantly lower in those with a C. jejuni infection. C. jejuni-positive patients were more severely affected, indicated by a lower Medical Research Council sum score at nadir (p = 0.004) and a longer time to regain the ability to walk independently (p = 0.005). The pure motor variant and axonal electrophysiologic subtype were more frequent in Asian compared with American or European C. jejuni-positive patients (p < 0.001, resp. p = 0.001). Time to nadir was longer in the cytomegalovirus-positive patients (p = 0.004). DISCUSSION: Across geographical regions, the distribution of infections was similar, but the association between infection and clinical phenotype differed. A mismatch between symptom reporting and serologic results and the high frequency of coinfections demonstrate the importance of broad serologic testing in identifying the most likely infectious trigger. The association between infections and outcome indicates their value for future prognostic models.
Asunto(s)
Infecciones por Campylobacter , Infecciones por Virus de Epstein-Barr , Síndrome de Guillain-Barré , Infecciones por Campylobacter/complicaciones , Infecciones por Campylobacter/epidemiología , Infecciones por Virus de Epstein-Barr/complicaciones , Síndrome de Guillain-Barré/diagnóstico , Herpesvirus Humano 4 , Humanos , InternacionalidadRESUMEN
OBJECTIVE: To determine whether rituximab is safe and potentially beneficial, warranting further investigation in an efficacy trial for acetylcholine receptor antibody-positive generalized MG (AChR-Ab+ gMG). METHODS: The B-Cell Targeted Treatment in MG (BeatMG) study was a randomized, double-blind, placebo-controlled, multicenter phase-2 trial that utilized a futility design. Individuals 21-90 years of age, with AChR-Ab+ gMG (MG Foundation of America Class II-IV) and receiving prednisone ≥15 mg/day were eligible. The primary outcome was a measure of steroid-sparing effect, defined as the proportion achieving ≥75% reduction in mean daily prednisone dose in the 4-weeks prior to week 52 and with clinical improvement or no significant worsening as compared to the 4-week period prior to randomization. The co-primary outcome was safety. Secondary outcomes included MG-specific clinical assessments. Fifty-two individuals were randomized (1:1) to either a two-cycle rituximab/placebo regimen, with follow-up through 52-weeks. RESULTS: Of the 52 participants included, mean (±SD) age at enrollment was 55.1 (±17.1) years; 23 (44.2%) were female, and 31 (59.6%) were MGFA Class II. The mean (±SD) baseline prednisone dose was 22.1 (±9.7) mg/day. The primary steroid-sparing outcome was achieved in 60% of those on rituximab vs. 56% on placebo. The study reached its futility endpoint (p=0.03) suggesting that the pre-defined clinically meaningful improvement of 30% due to rituximab over placebo was unlikely to be achieved in a subsequent, larger trial. No safety issues identified. CONCLUSIONS: While rituximab was safe and well-tolerated, these results suggest that there is a low probability of observing the defined clinically meaningful steroid-sparing effect over a 12-month period in a phase-3 trial of mild-moderately symptomatic AChR-Ab+ gMG. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that for mild-to-moderate AChR-Ab+ gMG, compared with placebo, rituximab is safe but unlikely to reduce steroid use by an absolute difference of at least 30% at 1 year. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02110706.
RESUMEN
Chest CT angiography (CTA) is essential in the diagnosis of acute aortic syndromes. Chest CTA quality can be optimized with attention to technical parameters pertaining to noncontrast imaging, timing of contrast-enhanced imaging, contrast material volume, kilovolt potential, tube-current modulation, and decisions regarding electrocardiographic-gating and ultra-fast imaging, which may affect the accurate diagnosis of acute aortic syndromes. An understanding of methods to apply to address suboptimal image quality is useful, as the accurate identification of acute aortic syndromes is essential for appropriate patient management. Acute aortic syndromes have high morbidity and mortality, particularly when involving the ascending aorta, and include classic aortic dissection, penetrating atherosclerotic ulcer, and acute intramural hematoma. An understanding of the pathogenesis and distinguishing imaging features of acute aortic syndromes and aortic rupture and some less common manifestations is helpful when interpreting imaging examinations. Related entities, such as ulcerated plaque, ulcerlike projections, and intramural blood pools, and mimics, such as vasculitis and aortic thrombus, are important to recognize; knowledge of these is important to avoid interpretive pitfalls. In addition, an awareness of postsurgical aortic changes can be useful when interpreting CTA examinations when patient history is incomplete. The authors review technical considerations when performing CTA, discuss acute aortic syndromes, and highlight diagnostic challenges encountered when interpreting aortic CTA examinations. ©RSNA, 2021.
Asunto(s)
Enfermedades de la Aorta , Disección Aórtica , Disección Aórtica/diagnóstico por imagen , Aorta , Enfermedades de la Aorta/diagnóstico por imagen , Angiografía por Tomografía Computarizada , Hematoma , Humanos , Tomografía Computarizada por Rayos XRESUMEN
IMPORTANCE: Myasthenia gravis (MG), an autoimmune disorder of neuromuscular transmission, is treated by an array of immunotherapeutics, many of which are nonspecific. Even with current therapies, a subset of patients has medically refractory MG. The benefits of B-cell-targeted therapy with rituximab have been observed in MG; however, the duration of these benefits after treatment is unclear. OBJECTIVE: To evaluate the durability of response to rituximab in the treatment of acetylcholine receptor autoantibody-positive (AChR+) generalized MG. DESIGN, SETTING AND PARTICIPANTS: This retrospective case series study included 16 patients with AChR+ MG referred to an MG clinic from January 1, 2007, to December 31, 2015. The patients were treated with rituximab and followed up for 18 to 84 months after treatment. MAIN OUTCOMES AND MEASURES: Assessment of long-term clinical response, durability of response and/or relapse rate, AChR autoantibody levels, adverse effects, and inflammatory markers. RESULTS: In the 16 patients (6 men and 10 women; median age, 42 [range, 18-69] years), clinical improvement was observed in parallel with complete withdrawal or reduction of other immunotherapies, with all patients achieving complete stable remission, pharmacologic remission, or minimal manifestations based on the Myasthenia Gravis Foundation of America postintervention status criteria. Nine patients (56%) had a relapse during a mean follow-up of 36 (range, 24-47) months. Seven patients (44%) remained relapse free with a mean follow-up of 47 (range, 18-81) months since the last rituximab treatment. All values were normalized to a pretreatment anti-AChR antibody level of 100% and the mean levels after each rituximab cycle were calculated. A 33% decrease was seen after cycle 1 of rituximab treatment (100% vs 67%; P = .004); 20% after cycle 2 (compared with cycle 1) (67% vs 47%; P = .008); and 17% after cycle 3 (compared with cycle 2) (47% vs 30%; P = .02). However, the serum cytokine levels measured were found to be unchanged. CONCLUSIONS AND RELEVANCE: Rituximab therapy appears to be an effective option in patients with refractory AChR+ MG, who were observed to have a durable response after treatment. Identification of markers of disease relapse and sustained remission are critical next steps in the development of pathophysiology-relevant, evidence-based practice parameters for rituximab in the treatment of MG.
Asunto(s)
Autoanticuerpos/sangre , Factores Inmunológicos/uso terapéutico , Miastenia Gravis/sangre , Miastenia Gravis/tratamiento farmacológico , Receptores Colinérgicos/inmunología , Rituximab/uso terapéutico , Adolescente , Adulto , Anciano , Femenino , Humanos , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Miastenia Gravis/inmunología , Proteómica/métodos , Estudios Retrospectivos , Resultado del Tratamiento , Adulto JovenAsunto(s)
4-Aminopiridina/análogos & derivados , Enfermedades de la Unión Neuromuscular/tratamiento farmacológico , Producción de Medicamentos sin Interés Comercial , Médicos/psicología , Bloqueadores de los Canales de Potasio/uso terapéutico , 4-Aminopiridina/uso terapéutico , Amifampridina , Humanos , Enfermedades de la Unión Neuromuscular/economía , Producción de Medicamentos sin Interés Comercial/economía , Producción de Medicamentos sin Interés Comercial/métodosRESUMEN
PURPOSE OF REVIEW: This article discusses the specific neurologic issues that arise in patients with rheumatic diseases such as rheumatoid arthritis, systemic lupus erythematosus, and Sjögren syndrome. Diagnosis and management are discussed. RECENT FINDINGS: Advances include advanced imaging, serologic and CSF markers, and targeted immune-modulating therapies. The use of these modalities are discussed in detail. SUMMARY: Rheumatic disorders are quite common and can result in disabling but many times treatable neurologic sequelae. The key is early diagnosis and management. Awareness of the common presentations and current modalities of diagnosis and treatment is critical to improved outcomes.
Asunto(s)
Enfermedades del Sistema Nervioso/etiología , Enfermedades Reumáticas/complicaciones , Adulto , Femenino , Humanos , Masculino , Persona de Mediana EdadAsunto(s)
Inmunomodulación , Síndrome de Miller Fisher/terapia , Corticoesteroides/administración & dosificación , Antiinflamatorios/administración & dosificación , Pueblo Asiatico , Femenino , Humanos , Inmunoglobulinas Intravenosas/administración & dosificación , Masculino , Metilprednisolona/administración & dosificación , Persona de Mediana Edad , Plasmaféresis , Recuperación de la Función/efectos de los fármacos , Estudios RetrospectivosAsunto(s)
Anticuerpos Monoclonales de Origen Murino/uso terapéutico , Autoanticuerpos/inmunología , Miastenia Gravis/tratamiento farmacológico , Miastenia Gravis/inmunología , Proteínas Tirosina Quinasas Receptoras/inmunología , Receptores Colinérgicos/inmunología , Adulto , Anticuerpos Monoclonales de Origen Murino/efectos adversos , Resistencia a Medicamentos/efectos de los fármacos , Femenino , Humanos , Masculino , Proteínas Tirosina Quinasas Receptoras/antagonistas & inhibidores , Estudios Retrospectivos , Rituximab , Resultado del TratamientoRESUMEN
BACKGROUND: A subset of myasthenia gravis (MG) patients is refractory to standard therapies. Identifying the characteristics of this population is essential as newer treatment strategies emerge that may be more effective in this group. OBJECTIVE: The aim of our study is to describe the clinical features of refractory MG patients and compare them to those of non-refractory patients. METHODS: A retrospective chart review was completed of 128 MG patients referred to a tertiary neuromuscular clinic from 2003 to 2011. Patients were classified as refractory or non-refractory based on predefined criteria, and clinical features were compared. RESULTS: Nineteen out of 128 patients were classified as refractory (14.8 percent). Compared to the non-refractory patients, the refractory patients were more likely to be younger at onset, female, thymomatous, and MuSK-antibody positive. CONCLUSION: Refractory MG patients represent a small but distinct group for whom exploring newer therapeutic approaches and immunopathologic differences is warranted.
Asunto(s)
Miastenia Gravis/patología , Adolescente , Adulto , Edad de Inicio , Anciano , Anticuerpos/metabolismo , Femenino , Humanos , Masculino , Miastenia Gravis/epidemiología , Miastenia Gravis/inmunología , Timectomía , Timoma/patología , Adulto JovenRESUMEN
Inclusion body myositis (IBM) belongs to a group of muscle diseases known as the inflammatory myopathies. The presence of antibody-secreting plasma cells in IBM muscle implicates the humoral immune response in this disease. However, whether the humoral immune response actively contributes to IBM pathology has not been established. We sought to investigate whether the humoral immune response in IBM both in the periphery and at the site of tissue damage was directed towards self-antigens. Peripheral autoantibodies present in IBM serum but not control serum recognized self-antigens in both muscle tissue and human-derived cell lines. To study the humoral immune response at the site of tissue damage in IBM patients, we isolated single plasma cells directly from IBM-derived muscle tissue sections and from these cells, reconstructed a series of recombinant immunoglobulins (rIgG). These rIgG, each representing a single muscle-associated plasma cell, were examined for reactivity to self-antigens. Both, flow cytometry and immunoblotting revealed that these rIgG recognized antigens expressed by cell lines and in muscle tissue homogenates. Using a mass spectrometry-based approach, Desmin, a major intermediate filament protein, expressed abundantly in muscle tissue, was identified as the target of one IBM muscle-derived rIgG. Collectively, these data support the view that IBM includes a humoral immune response in both the periphery and at the site of tissue damage that is directed towards self-antigens.
Asunto(s)
Autoanticuerpos/sangre , Autoinmunidad , Inmunidad Humoral , Inmunoglobulina G/sangre , Miositis por Cuerpos de Inclusión/inmunología , Animales , Autoanticuerpos/química , Autoanticuerpos/aislamiento & purificación , Autoantígenos/inmunología , Autoantígenos/aislamiento & purificación , Estudios de Casos y Controles , Línea Celular , Desmina/inmunología , Desmina/aislamiento & purificación , Humanos , Inmunoglobulina G/química , Inmunoglobulina G/aislamiento & purificación , Ratones , Proteínas Musculares/inmunología , Proteínas Musculares/aislamiento & purificación , Músculo Esquelético/inmunología , Músculo Esquelético/metabolismo , Músculo Esquelético/patología , Miositis por Cuerpos de Inclusión/sangre , Unión ProteicaRESUMEN
INTRODUCTION: Myasthenia gravis, an autoimmune disorder of neuromuscular transmission, is treated by an array of immunomodulating therapies. A variable response is observed with certain patients being medically refractory. METHODS: We report the results of 14 refractory generalized myasthenia gravis patients (6 AChR+; 8 MuSK+) treated with rituximab. RESULTS: Sustained clinical improvement was observed in all patients as well as a reduction of conventional immunotherapies. Prednisone dose decreased a mean of 65.1%, 85.7%, and 93.8% after cycle 1, 2, and 3 of rituximab therapy, respectively. A statistically significant reduction in plasma exchange sessions was seen after cycle 1 with all patients being off of plasma exchange after cycle 3. Acetylcholine receptor antibody titers decreased a mean of 52.1% (p = 0.0046) post-cycle 2. CONCLUSION: Our results support the hypothesis that rituximab is beneficial and well tolerated in managing refractory myasthenia gravis and nearly doubles published cases. We propose that B-cell-directed therapies may become an attractive option and suggest pursuit of a prospective trial.
Asunto(s)
Lesiones Encefálicas/metabolismo , Proteínas de Unión al ADN/metabolismo , Enfermedad de la Neurona Motora/metabolismo , Proteinopatías TDP-43/metabolismo , Lesiones Encefálicas/patología , Lesión Encefálica Crónica/metabolismo , Lesión Encefálica Crónica/patología , Humanos , Enfermedad de la Neurona Motora/patología , Factores de Riesgo , Proteinopatías TDP-43/patologíaRESUMEN
OBJECTIVE: To show the first clinically reported case of Cat Scratch Disease (CSD) presenting as a focal neurologic deficit in an immunocompetent adult. PATIENT: 59-year-old male with a history of a previous stroke. RESULTS: Examination showed an expressive aphasia, word substitution errors, and impaired repetition. A head CT and MRI showed no acute changes. The EEG findings were non-focal and did not show any epileptiform activity. The patient had a history of contact with stray kittens and previous axillary lymphadenopathy. Bartonella henselae serology titers were IgG positive 1:1024 (< 64) and IgM positive 1:20 (< 16). After antibiotic administration, the patient's symptoms and aphasia resolved. CONCLUSIONS: Focal presentations concerning for stroke or partial seizure activity may have underlying infectious etiology. We recommend consideration of CSD in the differential diagnosis of any adult with a history of lymphadenopathy, fever, and recent contact with a cat who presents with neurologic complications.
Asunto(s)
Afasia de Broca/etiología , Infecciones por Bartonella/complicaciones , Bartonella henselae/aislamiento & purificación , Encefalitis/complicaciones , Inmunocompetencia , Antibacterianos/administración & dosificación , Afasia de Broca/diagnóstico por imagen , Afasia de Broca/fisiopatología , Infecciones por Bartonella/diagnóstico por imagen , Infecciones por Bartonella/microbiología , Infecciones por Bartonella/fisiopatología , Electroencefalografía , Encefalitis/diagnóstico por imagen , Encefalitis/microbiología , Encefalitis/fisiopatología , Humanos , Masculino , Persona de Mediana Edad , Tomografía Computarizada por Rayos X , Resultado del TratamientoRESUMEN
Myasthenia gravis (MG) is an immune-mediated disorder with a variable response to treatment. In this study, patients with refractory MG who were treated with rituximab were identified. A review of patients referred to the Yale Neuromuscular Clinic was performed. Patients with refractory MG who were treated with rituximab were reviewed for response to treatment. Patients who had muscle-specific kinase (MuSK(+)) or acetylcholine receptor (AChR(+)) antibodies were included. Six patients were identified who met the criteria described. All patients tolerated rituximab without side effects and had a reduced need for immunosuppressants and/or improvement in clinical function. Patients with refractory MG appeared to respond to rituximab in this small, retrospective study. This result suggests that a larger, prospective trial is indicated.
Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Miastenia Gravis/tratamiento farmacológico , Antiinflamatorios/uso terapéutico , Anticuerpos Monoclonales de Origen Murino , Inhibidores de la Colinesterasa/uso terapéutico , Supervivencia sin Enfermedad , Esquema de Medicación , Femenino , Humanos , Inmunoglobulinas Intravenosas/uso terapéutico , Factores Inmunológicos/uso terapéutico , Persona de Mediana Edad , Miastenia Gravis/inmunología , Prednisona/uso terapéutico , Bromuro de Piridostigmina/uso terapéutico , Proteínas Tirosina Quinasas Receptoras/inmunología , Receptores Colinérgicos/inmunología , Estudios Retrospectivos , Rituximab , Resultado del TratamientoRESUMEN
In the present study, we investigated whether attention to faces results in sensory gain modulation. Participants were cued to attend either to faces or to scenes in superimposed face-scene images for which face discriminability was manipulated parametrically. The face-sensitive N170 event-related potential component was used as a measure of early face processing. Attention to faces modulated N170 amplitude, but only when faces were not highly discriminable. Additionally, directing attention to faces modulated later processing (~230-300 msec) for all discriminability levels. These results demonstrate that attention to faces can modulate perceptual processing of faces at multiple stages of processing, including early sensory levels. Critically, the early attentional benefit is present only when the "face signal" (i.e., the perceptual quality of the face) in the environment is suboptimal.
Asunto(s)
Atención/fisiología , Aprendizaje Discriminativo/fisiología , Potenciales Evocados Visuales/fisiología , Cara , Memoria a Corto Plazo/fisiología , Reconocimiento Visual de Modelos/fisiología , Enmascaramiento Perceptual/fisiología , Tiempo de Reacción/fisiología , Adulto , Corteza Cerebral/fisiología , Electroencefalografía , Femenino , Humanos , Masculino , Orientación/fisiología , Procesamiento de Señales Asistido por Computador , Adulto JovenRESUMEN
Fifty percent of ocular myasthenia gravis (OMG) patients will progress to generalized myasthenia, 90% within 3 years from the onset of ocular symptoms. This study was performed to determine whether treatment with oral prednisone initiated and completed within 2 years from the onset of ocular symptoms would affect the progression of ocular myasthenia to generalized myasthenia gravis (GMG). Fifty-six patients were included in this review, with 27 patients in the prednisone-treated group and 29 patients in the untreated group. The treated group was initiated on 60 mg of prednisone daily with a slow taper over 3-6 months. At 2 years, significantly fewer patients in the treated group (3 of 27) progressed to generalized myasthenia when compared to the untreated group (10 of 29) (chi(2), p=0.04). Our results suggest that the early use of steroids may decrease progression of ocular to generalized myasthenia gravis. The decision to use steroids should be considered early in the course of patients diagnosed with ocular myasthenia gravis. This study should be considered preliminary and a prospective trial is warranted to confirm our observations.
Asunto(s)
Inmunosupresores/uso terapéutico , Miastenia Gravis/tratamiento farmacológico , Miastenia Gravis/prevención & control , Prednisona/uso terapéutico , Inhibidores de la Colinesterasa/uso terapéutico , Progresión de la Enfermedad , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Femenino , Humanos , Masculino , Persona de Mediana Edad , Miastenia Gravis/fisiopatología , Músculos Oculomotores/efectos de los fármacos , Músculos Oculomotores/inmunología , Músculos Oculomotores/fisiopatología , Bromuro de Piridostigmina/uso terapéutico , Receptores Colinérgicos/efectos de los fármacos , Receptores Colinérgicos/inmunología , Estudios Retrospectivos , Resultado del TratamientoRESUMEN
Multifocal motor neuropathy (MMN) is a chronic, immune-mediate, peripheral myelinopathy. Inherent in its name, MMN implies involvement of two or more motor nerves. We report three patients with weakness and partial motor conduction block restricted to a single nerve and localized to sites that are not at risk for entrapment or compression injury. None of the patients had sensory involvement and all showed a favorable response to intravenous immunoglobulin therapy. Based on these observations and reports of three additional patients, we believe that monofocal motor neuropathy is a partial form of MMN and should be treated as such.